Abstract
Since its introduction in 1954 by Murray and colleagues, allotransplantation has greatly improved the quality, as well as the duration of life for those involved.1 The discovery of immunosuppressant drugs advanced long term efficacy of transplantation and led to a further improvement in the quality of life. Unfortunately, maximal potential benefits have never been achieved. As with a number of other organs, particularly kidneys, livers and hearts, there are lengthy waiting lists for suitable lungs. This lack of sufficient organs results, not only from the limited number of donors, but in part because many of the lungs available for transplant are judged unsuitable, due to edema, aspiration or contusion. The short period over which lungs remain clinically viable, presently 6–8 hours, also limits the availability of these organs. Furthermore, the practice of maintaining brain-damaged potential organ donors on respirators using high oxygen levels and vigorous mechanical ventilation contributes to the paucity of available lungs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R.P. Lanza, D.K.C. Cooper, and W.L. Chick, Xenotransplantation, Sci Am. 277:54 (1997).
F. Possmayer, Physicochemical aspects of pulmonary surfactant, in: Fetal and Neonatal Physiology, R.A. Poulin and W.W. Fox, eds., WB Saunders Company, Boca Raton (1997). (in press)
R.J. King and J.A. Clements, Surface active materials from dog lung. II. Composition and physiological correlations, A m J Phys. 223:715 (1972).
R.A.W. Veldhuizen, J. Lee, D. Sandler, W. Hull, J.A. Whitsett, F. Possmayer and R.J. Novick, Alterations in pulmonary surfactant composition and activity after experimental lung transplantation, Am Rev Respir Dis. 148:208 (1993).
L.A.J.M. Creuwels, L.M.G. van Golde and H.P. Haagsman, The Pulmonary surfactant system: biochemical and clinical aspects, Lung. 175:1 (1997).
J. Johansson, and T. Curstedt, Molecular structures and interactions of pulmonary surfactant components, Eur J Biochem. 244:675 (1997).
L.M.G. van Golde, J.J. Batenburg and B. Robertson, The pulmonary surfactant system, Int Union Physiol SciJ/Am Physiol Soc. 9:13 (1994).
N.J. Gross, Extracellular metabolism of pulmonary surfactant: the role of a new serine protease, Annu Rev Physiol. 57:135 (1995).
J.F. Lewis and A.H. Jobe, Surfactant and the adult respiratory distress syndrome, Am Rev Respir Dis. 147:218 (1993).
J.F. Lewis and R.A.W. Veldhuizen, Factors influencing efficacy of exogenous surfactant in acute lung injury, Biol Neonate. 67: 48 (1995).
U.S. Yu, N. Smith, P.G.R. Harding and F. Possmayer, Bovine pulmonary surfactant: Chemical composition and physical properties, Lipids. 18:522 (1983).
J.F. Lewis, J.S. Dhillon, R. Singh, C.C. Johnson and T.C. Frewen, Exogenous surfactant therapy for pediatric patients with the acute respiratory distress syndrome, Can Resp J. 4:21 (1997).
R.J. Novick, R.A.W. Veldhuizen, F. Possmayer, J. Lee, D. Sandler, and J.F. Lewis, Exogenous surfactant therapy in thirty-eight hour lung graft preservation for transplantation, J Thorac Cardiovasc Surg. 108:259 (1994).
R.J. Novick, J. MacDonald, R.A.W. Veldhuizen, J. Duplan, L. Denning, F. Possmayer, A. Gilpin, L.J. Yao, D. Bjarneson and J.F. Lewis., Evaluation of surfactant treatment strategies after prolonged graft storage in lung transplantation, Am J Respir Crit Care Med. 154:98 (1996).
R.J. Novick, A.A. Gilpin, K.E. Gehman, LS. Ali, R.A.W. Veldhuizen, J. Duplan, L. Denning, F. Possmayer, D. Bjarneson and J.F. Lewis, Mitigation of injury in canine lung grafts by exogenous surfactant therapy, J Thorac Cardio Vase Surg. 113:342 (1997).
D.S. Strayer, E. Herting, B. Sun and B. Robertson, Antibody to surfactant protein A increases sensitivity of pulmonary surfactant inactivation by fibrinogen in vivo, Am J Resp Crit Care Med. 153:1116 (1996).
K. Yukitake, C.L. Brown, M.A. Schlueter, J.A. Clements and S. Hawgood, Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo, Pediatr Res. 37:21 (1995).
M.E. Erasmus, A.H. Petersen, G. Hofstede, H.P. Haagsman, S.B. Oetomo and J. Prop Surfactant treatment before reperfusion improves the immediate function of lung transplants in rats, Am J Respir Crit Care Med. 153:665 (1996).
M.E. Erasmus, A.H. Petersen, S.B. Oetomo and J. Prop, The function of surfactant is impaired during the reimplantation response in rat lung transplants, J Heart Lung Transplan. 13:791 (1994).
Novick, R.J., Gehman, K.E., Ali, LS., and Lee, J., 1996 Lung preservation — the importance of endothelial and alveolar type II cell integrity, Ann Thorac Surg. 62:302.
A. Günther, I. Friedrich, F.H. Splittgerber, J. Börgermann, M. Brinkmann, R. Schmidt, M. Yabut, C. Reidemeister and W. Seeger, Attenuation of reperfusion-induced alteration of surfactant properties by application of bovine surfactant extract in a model of single lung transplantation, Am J Resp Crit Care Med. 155: A214. (1991).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Plenum Press, New York
About this chapter
Cite this chapter
Possmayer, F., Novick, R.J., Veldhuizen, R.A.W., Lee, J., Bjarneson, D., Lewis, J.F. (1998). Potential Role for Pulmonary Surfactant in Lung Transplantation. In: Matalon, S., Sznajder, J.L. (eds) Acute Respiratory Distress Syndrome. NATO ASI Series, vol 297. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8634-4_14
Download citation
DOI: https://doi.org/10.1007/978-1-4419-8634-4_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-45830-9
Online ISBN: 978-1-4419-8634-4
eBook Packages: Springer Book Archive